Please assess the completion status of the following clinical trial:

Trial Title: Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ≥18 years of age;~* Histological or cytological confirmation of adenocarcinoma of the colon or/and rectum;~* Subjects with metastatic colorectal cancer (CRC) whose disease progressed or who were intolerant to standard chemotherapy based on fluoropyrimidine, oxaliplatin, irinotecan, and an anti-EGFR therapy if RAS wild-type. This progression must be during or within 4 months following the last administration of standard therapies.~* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, Version 1.1.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Adequate bone-marrow, liver, and renal function~* Women of childbearing potential and men must agree to use adequate contraception when sexually active during the study and for at least 8 weeks after the last study drug administration.~Exclusion Criteria:~* Prior treatment with an antiangiogenic agent;~* Congestive heart failure of New York Heart Association (NYHA) class 2 or worse;~* Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction less than 6 months before start of study drug;~* Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)~* Uncontrolled hypertension (systolic blood pressure \>140 mmHg or diastolic pressure \>90 mmHg despite optimal medical management);~* Ongoing acute or chronic infection (\> Grade 2 NCI-CTCAE v 4.03);~* Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism (except for adequately treated catheter-related venous thrombosis occurring more than one month before the start of study medication) events within 6 months of study enrollment. Subjects being treated with low-weight heparin are allowed to participate as long as dose is limited to prophylactic use.~* Any history of or currently known brain metastases (head CT/MRI will be performed during screening period if brain metastases are suspected)~* Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years before study entry, except for curatively treated cervical cancer in situ, in situ ductal breast cancer, non-melanoma skin cancer and superficial bladder tumors;~* Last chemotherapy dose or any other anti-cancer therapy administered in less than 4 weeks from start of study treatment;~* Use of therapeutic anticoagulation;~* Proteinuria \> 3.5 g/24 hours measured by urine protein-creatinine ratio from a random urine sample (Grade 3, NCI-CTCAE v 4.03) on urinalysis screening result. If there is medical history of proteinuria, previous urinalysis results should be considered and/or performed so at least 2 results separated by at least 2 weeks are available;~* History of interstitial lung disease with ongoing signs and symptoms at the time of informed consent;~* Non-healing wound, non-healing ulcer, or non-healing bone fracture;~* Subjects with evidence or history of any bleeding diathesis, irrespective of severity;~* Any hemorrhage or bleeding event ≥ Grade 3 NCI-CTCAE v 4.03 within 4 weeks prior to the start of study medication;~* Known history of human immunodeficiency virus (HIV) infection;~* History of active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy;~* Pregnancy or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regorafenib (BAY73-4506) (Type: EXPERIMENTAL): Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).

Based on this trial design, predict the completion outcome and termination type (if applicable).